Astria Therapeutics Stockholders Approve Acquisition by BioCryst Pharmaceuticals

summarizeSummary

Astria Therapeutics' stockholders have approved the merger agreement with BioCryst Pharmaceuticals, Inc., with the acquisition expected to close around January 23, 2026.

check_boxKey Events

• Merger Agreement Approved

  Stockholders approved the Agreement and Plan of Merger with BioCryst Pharmaceuticals, Inc. with 35,673,135 votes for, representing approximately 62.49% of outstanding shares, well exceeding the required majority.

• Merger-Related Compensation Approved

  Stockholders also approved, on a non-binding advisory basis, the merger-related named executive officer compensation.

• Anticipated Closing Date

  The acquisition is expected to close on or about January 23, 2026, subject to the satisfaction of customary closing conditions.

auto_awesomeAnalysis

Astria Therapeutics' stockholders have overwhelmingly approved the previously announced merger agreement with BioCryst Pharmaceuticals, Inc. This approval is a critical step towards the completion of the acquisition, signaling a fundamental change in Astria's corporate structure and future operations. The expected closing date of January 23, 2026, indicates the transaction is moving swiftly towards finalization, which will result in Astria becoming a wholly-owned subsidiary of BioCryst. Investors should note that this marks the near-final stage of the acquisition process.